These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 7646568)
1. Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate. Chen CL; Sangiah S; Roder JD; Chen H; Berlin KD; Garrison GL; Scherlag BJ; Lazzara R Arzneimittelforschung; 1995 Jun; 45(6):670-5. PubMed ID: 7646568 [TBL] [Abstract][Full Text] [Related]
2. Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice. Chen CL; Chandra SA; Kim S; Sangiah S; Chen H; Roder JD; Qualls CW; Garrison GL; Cowell RL; Berlin KD; Scherlag BJ; Lazzara R Arzneimittelforschung; 2000 Jan; 50(1):31-8. PubMed ID: 10683713 [TBL] [Abstract][Full Text] [Related]
3. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472 [TBL] [Abstract][Full Text] [Related]
4. Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart. Fazekas T; Scherlag BJ; Carlsson L; Mabo P; Patterson E; Berlin KD; Lazzara R Acta Physiol Hung; 1995; 83(1):13-30. PubMed ID: 7660832 [TBL] [Abstract][Full Text] [Related]
5. Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. Garrison GL; Berlin KD; Scherlag BJ; Lazzara R; Patterson E; Fazekas T; Sangiah S; Chen CL; Schubot FD; van der Helm D J Med Chem; 1996 Jun; 39(13):2559-70. PubMed ID: 8691454 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of bisaramil in man. Gémesi L; Kapás M; Matos L Acta Pharm Hung; 1993 Nov; 63(6):327-33. PubMed ID: 8116453 [TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine. Chen CL; Lesseley BA; Clarke CR; Roder JD; Sangiah S; Berlin KD; Garrison GL; Scherlag BJ; Lazzara R; Patterson E J Chromatogr; 1992 Dec; 583(2):274-9. PubMed ID: 1478994 [TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic method for quantitative determination of Yutac, a new antiarrhythmic agent, in dog plasma. Rónai-Lukács S; Kozma M; Vereczkey L J Chromatogr; 1985 Mar; 338(2):428-32. PubMed ID: 3998028 [No Abstract] [Full Text] [Related]
9. Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. Roder JD; Chen CL; Chen H; Sangiah S J Vet Pharmacol Ther; 1996 Jun; 19(3):200-4. PubMed ID: 8803878 [TBL] [Abstract][Full Text] [Related]
10. Analytical determination and pharmacokinetics of robenacoxib in the dog. Jung M; Lees P; Seewald W; King JN J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of AR-L 115 BS in rabbits and dogs]. Zimmer A; Hammer R Arzneimittelforschung; 1981; 31(1a):212-6. PubMed ID: 7195224 [TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole. Conte L; Ramis J; Mis R; Vilageliu J; Basi N; Forn J Arzneimittelforschung; 1992 Jun; 42(6):854-8. PubMed ID: 1418045 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in laboratory animals. Komuro M; Hori W; Hotta M; Saitoh S; Ishida R; Uchida H Arzneimittelforschung; 1992 Jan; 42(1):55-9. PubMed ID: 1586381 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. Brunner F; Kolmayr U; Kukovetz WR Arzneimittelforschung; 1989 Nov; 39(11):1430-5. PubMed ID: 2619776 [TBL] [Abstract][Full Text] [Related]
17. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614 [TBL] [Abstract][Full Text] [Related]
18. Repeated dose pharmacokinetics of pancopride in human volunteers. Salva P; Costa J; Pérez-Campos A; Martínez-Tobed A Biopharm Drug Dispos; 1994 Nov; 15(8):643-51. PubMed ID: 7888596 [TBL] [Abstract][Full Text] [Related]
19. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man. Scatina JA; Hicks DR; Kraml M; Cayen MN Eur J Drug Metab Pharmacokinet; 1990; 15(1):37-48. PubMed ID: 2384116 [TBL] [Abstract][Full Text] [Related]
20. Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent. Chen CL; Sangiah S; Bourne DW; Roder JD; Chen H; Alavi FK; Clarke CR; Garrison GL; Berlin KD; Couch KM Eur J Drug Metab Pharmacokinet; 1995; 20(2):151-61. PubMed ID: 8582441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]